Prognostic and Clinical Values of Chaperone Protein P4HB in Malignant Glioma

Introduction. Prolyl 4-hydroxylase, beta polypeptide (P4HB) has previously been identified by our group to play important roles in association with glioma malignancy and temozolomide (TMZ) resistance through the unfolded protein response (UPR). The present study focused on the prognostic value of P4HB in glioma. Methods. P4HB expression was assessed by immunohistochemical staining and semi-quantified by pathologist visual scoring in 73 WHO grade I-IV gliomas. Results were correlated with clinicopathological data. Results. Our results show that P4HB expression was significantly associated several clinicopathological parameters including age (p=0.035), tumour grade (p=0.002), and the number of TMZ treatment cycles received (p=0.043). Using Kaplan-Meier analysis, P4HB expression was positively correlated with mortality (p=0.014) and disease progression (p=0.026). In patients treated with TMZ, high P4HB expression level was significantly associated with poorer overall survival (OS) (p=0.014) and progression free survival (PFS) (p=0.027). The association between MGMT promoter methylation and P4HB expression was also interrogated. Patients with MGMTMethP4HBLow tumours had the most favourable progression free survival (48 months) than patients with other combination of MGMT methylation status and P4HB expression (log rank p=0.001). Multivariate analysis revealed that P4HB was an independent prognostic indicator for OS (p=0.048). Conclusions. P4HB could constitute an independent prognostic marker, especially for high grade glioma with the potential for informing a nuanced pathological stratification during clinical decision-making with respect to MGMT promoter methylation status and TMZ treatment.

[1]  F. Attenello,et al.  Characterizing Cell Stress and GRP78 in Glioma to Enhance Tumor Treatment , 2020, Frontiers in Oncology.

[2]  Xi Chen,et al.  Endoplasmic reticulum stress signals in the tumour and its microenvironment , 2020, Nature Reviews Cancer.

[3]  H. Friedman,et al.  Management of glioblastoma: State of the art and future directions. , 2020, CA: a cancer journal for clinicians.

[4]  Hui Cao,et al.  Protein disulfide isomerases are promising targets for predicting the survival and tumor progression in glioma patients , 2020, Aging.

[5]  P. Perrini,et al.  Multiple high-grade gliomas: epidemiology, management, and outcome. A systematic review and meta-analysis , 2019, Neurosurgical Review.

[6]  N. Neamati,et al.  Activation of the Unfolded Protein Response via Inhibition of Protein Disulfide Isomerase Decreases the Capacity for DNA Repair to Sensitize Glioblastoma to Radiotherapy. , 2019, Cancer research.

[7]  A. Brandes,et al.  Temozolomide rechallenge in recurrent glioblastoma: when is it useful? , 2018, Future Oncology.

[8]  P. Day,et al.  Endoplasmic reticulum chaperone prolyl 4-hydroxylase, beta polypeptide (P4HB) promotes malignant phenotypes in glioma via MAPK signaling , 2017, Oncotarget.

[9]  F. Kruyt,et al.  The endoplasmic reticulum stress/unfolded protein response in gliomagenesis, tumor progression and as a therapeutic target in glioblastoma. , 2016, Biochemical pharmacology.

[10]  Chris Jones,et al.  Endoplasmic reticulum stress-inducing drugs sensitize glioma cells to temozolomide through downregulation of MGMT, MPG, and Rad51. , 2016, Neuro-oncology.

[11]  Anne Clavreul,et al.  Toward an effective strategy in glioblastoma treatment. Part I: resistance mechanisms and strategies to overcome resistance of glioblastoma to temozolomide. , 2015, Drug discovery today.

[12]  A. Asher,et al.  Polymeric drug delivery for the treatment of glioblastoma. , 2015, Neuro-oncology.

[13]  N. Chattipakorn,et al.  Current evidence of temozolomide and bevacizumab in treatment of gliomas , 2015, Neurological research.

[14]  Wei Xiong,et al.  Potential roles for Gfi1 in the pathogenesis and proliferation of glioma. , 2013, Medical hypotheses.

[15]  P. Day,et al.  Inhibition of prolyl 4-hydroxylase, beta polypeptide (P4HB) attenuates temozolomide resistance in malignant glioma via the endoplasmic reticulum stress response (ERSR) pathways. , 2013, Neuro-oncology.

[16]  Amy S. Lee,et al.  The critical roles of endoplasmic reticulum chaperones and unfolded protein response in tumorigenesis and anticancer therapies , 2013, Oncogene.

[17]  S. Kohsaka,et al.  STAT3 Inhibition Overcomes Temozolomide Resistance in Glioblastoma by Downregulating MGMT Expression , 2012, Molecular Cancer Therapeutics.

[18]  Philip J. R. Day,et al.  LABORATORY INVESTIGATION- HUMAN/ANIMAL TISSUE Protein , 2022 .

[19]  R. Kaufman,et al.  The endoplasmic reticulum and the unfolded protein response. , 2007, Seminars in cell & developmental biology.

[20]  Burton H Singer,et al.  Combinations of biomarkers predictive of later life mortality , 2006, Proceedings of the National Academy of Sciences.

[21]  Martin J. van den Bent,et al.  Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. , 2005, The New England journal of medicine.

[22]  R. Mirimanoff,et al.  MGMT gene silencing and benefit from temozolomide in glioblastoma. , 2005, The New England journal of medicine.